US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Orexo acquires exclusive US rights to commercialize deprexis®, a world-leading digital therapy to help patients manage the symptoms of depression

    -Scientifically proven digital therapy further strengthens commitment to digital therapeutics -Significant commercial potential -COVID-19 expected to create a significant rise in clinical depression -Leveraging existing US infrastructure Uppsala, Sweden – May 11, 2020. Orexo AB (publ.) today announces it has acquired the exclusive US rights to GAIA AG´s (GAIA) deprexis®, a digital therapy to help patients manage their symptoms of depression and one of the most researched digital therapies in the world. Today’s announcement follows two earlier agreements with GAIA where Orexo

    Orexo submits application for vorvida® to the FDA to enable commercialization in the US

    ·  vorvida® clearance from FDA anticipated Q2 2020 · expects to launch its first digital therapy in the US for heavy alcohol use in H2 2020 Uppsala, Sweden – March 6, 2020. Orexo AB (publ), today announces it has submitted an application to the US Food and Drug Administration (FDA) for vorvida® to enable commercialization in the US. vorvida®, is a digital therapy with clinically proven efficacy for the treatment of bothersome or harmful alcohol consumption including diagnosed alcohol use disorder (AUD). Subject to hearing from the FDA, which is expected during the second quarter of

    Orexo Interim Report Q3 2019

    Strong financials paving the way for broadening the business Q3 2019 highlights · Total net revenues of SEK 231.2 million (216.6), up 6.7 percent · Zubsolv® US net revenues of SEK 182.7 million (165.4), up 10.4 percent in SEK and 3.0 percent in local currency · EBITDA of SEK 114.1 million (39.8), up 186.7 percent. EBITDA ex Abstral® of SEK 71.7 million (-8.9). · US EBIT of SEK 93.4 million (55.6), up 68.0 percent · Cash flow from operating activities of SEK 135.7 million (24.5), building a cash balance of SEK 812.9 million (516.6) · Net earnings of SEK 111.7 million (

    Orexo signs partnership agreement with GAIA to develop and commercialize a new digital therapy for the treatment of Opioid Use Disorder

    Uppsala, Sweden – August 20, 2019. Orexo AB (publ), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces it has entered into an exclusive agreement with GAIA AG (GAIA), a global leader in digital therapeutics that successfully launched its first digital health product in 2001, for a new digital therapy (DTx) for the treatment of Opioid Use Disorder (OUD). Orexo will have the exclusive global commercial rights to the product and intends to launch it in the US in 2022, subject to regulatory approval. The medically assisted treatment of

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media